MAFA
INO icon

MJT & Associates Financial Advisory’s Inovio Pharmaceuticals INO Stock Holding History

MJT & Associates Financial Advisory’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-325
Closed -$358 – 454
2026
Q2 		$358 Hold
325
– – ﹤0.01% 444
2026
Q1 		$566 Hold
325
– – ﹤0.01% 416
2025
Q4 		$566 Hold
325
– – ﹤0.01% 420
2025
Q3 		$761 Hold
325
– – ﹤0.01% 427
2025
Q2 		$661 Hold
325
– – ﹤0.01% 439
2025
Q1 		$530 Buy
+325
New +$652 ﹤0.01% 447

Other funds holding INO

GAA
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
BAM
Byrne Asset Management Kingston, New Jersey $179M AUM 29.67% 1-Year Est. Return

MJT & Associates Financial Advisory's INO Position: Q3 2026 in Review

MJT & Associates Financial Advisory sold out of Inovio Pharmaceuticals (INO) in Q3 2026, closing a stake of 325 shares — an estimated $358 sold.

MJT & Associates Financial Advisory first reported a position in INO in Q1 2025 and held it in 6 quarters. The position peaked at $761 in Q3 2025. 5 funds tracked by Wall St. Rank hold INO as of Q3 2026.

  • MJT & Associates Financial Advisory reported no remaining Inovio Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • MJT & Associates Financial Advisory sold 325 Inovio Pharmaceuticals shares in Q3 2026, an estimated $358.
  • MJT & Associates Financial Advisory first reported a position in Inovio Pharmaceuticals in Q1 2025 and held it in 6 quarters.
  • MJT & Associates Financial Advisory's Inovio Pharmaceuticals position peaked at $761 in Q3 2025.
  • 5 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2026.

Based on MJT & Associates Financial Advisory's 13F filing for Q3 2026, filed 7 Oct 2026.